Melanoma is one of Australia’s most common cancers with over 13,000 new diagnoses per year in Australia. In one out of ten patients, the melanoma diagnosis comes too late, as the melanoma has already spread throughout the body, drastically diminishing the chances of survival. With more than 1,700 Australians dying every year from melanoma - one every 5 hours, we urgently require a better understanding of how the melanoma spreads and why certain tumours respond to current treatment while others are resistant to treatment.
As part of the Centre for Precision Health, our research aims to develop non-invasive blood-based tests to enable personalised cancer monitoring and facilitate therapeutic decisions. Our focus is on the analysis of biomarkers such as circulating tumour cells (CTCs), circulating tumour DNA (ctDNA), extracellular vesicles and autoantibodies.
Historically, our research has focused on melanoma biomarkers. Given the interest across the oncology field in liquid biopsies, we are now applying our expertise for research projects in lung, ovarian, breast and other cancers.
We use cutting-edge methods such as droplet digital PCR, next-generation sequencing, microfluidic devices and single-cell RNA sequencing that allow sensitive measurement of these rare cells and DNA mutations. Translational projects explore the relationship between these biomarkers and disease progression, drug resistance, tumour genetic evolution and treatment outcomes, to further their clinical implications and define their specific context of use.
No results were found
Please leave a comment about your rating so we can better understand how we might improve the page.